Loading...
•
Mar 31, 2024
Cue Biopharma Q1 2024 Earnings Report
Reported collaboration revenue increase and advanced clinical trials.
Key Takeaways
Cue Biopharma reported a collaboration revenue increase due to the Ono Pharmaceutical agreement and advancements in clinical trials for CUE-101 and CUE-102. The company's cash and cash equivalents are expected to fund operations into the first quarter of 2025.
CUE-101 and CUE-102 abstracts accepted for presentations at ASCO 2024.
Advanced preclinical CUE-401 program in collaboration with Ono Pharmaceutical.
Expanded pipeline with CUE-500 series for autoimmune and inflammatory diseases.
Immuno-STAT™ platform posters accepted for presentation at PEGS Boston Summit 2024.
Revenue by Segment
Forward Guidance
The company expects its current cash and cash equivalents to fund operations into the first quarter of 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...